Humacyte (NASDAQ:HUMA) Trading Down 6.4% – Should You Sell?

Humacyte, Inc. (NASDAQ:HUMA)’s stock price fell 6.4% on Tuesday . The stock traded as low as $4.11 and last traded at $4.11. 1,055,356 shares were traded during trading, a decline of 68% from the average session volume of 3,293,323 shares. The stock had previously closed at $4.39.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HUMA. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Monday. HC Wainwright restated a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. Finally, BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humacyte has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Price Performance

The firm has a fifty day moving average of $4.66 and a 200 day moving average of $5.69. The company has a market capitalization of $519.80 million, a P/E ratio of -3.08 and a beta of 1.32. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at $10,743,521.28. The trade was a 25.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Brookstone Capital Management purchased a new position in shares of Humacyte during the 4th quarter valued at about $56,000. Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. purchased a new position in shares of Humacyte during the 2nd quarter valued at about $83,000. FORA Capital LLC purchased a new position in shares of Humacyte during the 3rd quarter valued at about $96,000. Finally, Insigneo Advisory Services LLC purchased a new position in shares of Humacyte during the 3rd quarter valued at about $109,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.